Talphera Inc TLPH

Healthcare

Talphera, Inc., formerly AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Niyad is focused on developing regional anticoagulants for injection into the extracorporeal circuit, such as the dialysis circuit during continuous renal replacement therapy (CRRT) for acute kidney injury (AKI) patients in the hospital, and for chronic kidney disease patients undergoing intermittent hemodialysis (IHD) in dialysis centers. LTX-608 is nafamostat formulation for direct intravenous (IV) infusion that shall be investigated and developed as a potential anti-viral for the treatment of COVID, acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), and acute pancreatitis. The Company is also engaged in developing two pre-filled syringes, namely Fedsyra and PFS-02.

NDAQ:TLPH - Post by User

Talphera Inc

Bullboard Posts

Post by coffeygon Nov 15, 2012 12:36pm

539 Views

Post# 20605142

What's poignant ACRX into a Blazing Stock...

ACRX achieve a huge landmark today as an new high,$ACRX on 1440174 volume. I would have never estimated it but if you stare at the trends and news that bloomed about,the signs were leading towards this way.In my belief may appear like a fine play for the subsequent week, but if there is nothing else supporting it up, I have a burly feeling that it may fall back down to 1.76. Go after on what top analytics are saying

https://hotpennystocknews.com/V1.5/index.php?code=ACRX

Bullboard Posts

2024, a breakthrough year for silver